Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00983580 · ClinicalTrials.gov registry record · Phase 2
Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 107
- Enrollment target
NCT00983580: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00983580 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 107 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00983580, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 107 participants
- Enrollment target
Study Summary
This phase II trial is studying how well giving acetylsalicylic acid together with eflornithine works in treating patients at high risk for colorectal cancer. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of acetylsalicylic acid and eflornithine may prevent colorectal cancer.
Interventions
- OTHER Placebo
- OTHER Laboratory Biomarker Analysis
- DRUG Aspirin
- DRUG Eflornithine
- OTHER Telephone-Based Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2009-08-20 |
| Est. Completion | 2019-08-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00983580
The ClinicalTrials.gov registry entry for NCT00983580 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT00983580 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00983580 about?
NCT00983580 is a clinical study titled "Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer". This phase II trial is studying how well giving acetylsalicylic acid together with eflornithine works in treating patients at high risk for colorectal cancer. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of acetylsalicylic acid and eflornithine may prevent colorec...
What is the current status of trial NCT00983580?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 107 participants. The study started on 2009-08-20. Estimated completion is 2019-08-13.
What interventions are being tested in trial NCT00983580?
The interventions under investigation include: Placebo (OTHER), Laboratory Biomarker Analysis (OTHER), Aspirin (DRUG), Eflornithine (DRUG), Telephone-Based Intervention (OTHER).
Who is sponsoring clinical trial NCT00983580?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.